![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, September 01, 2021 4:45:07 PM
As previously disclosed, on August 23, 2021, Cara Therapeutics, Inc. (“Cara”) received approval of its New Drug Application for KORSUVA™ injection for the treatment of moderate-to-severe pruritus in hemodialysis patients from the U.S. Food and Drug Administration (the “Approval Milestone”). Pursuant to a securities purchase agreement (the “Purchase Agreement”) between Cara and Vifor (International) Ltd. (“Vifor Pharma”), dated October 15, 2020, Cara is eligible to receive $50 million common stock investment at a 20% premium to the 30-day trailing average price of Cara’s common stock ending on the date immediately prior to the achievement of the Approval Milestone. A description of the Purchase Agreement is included in Cara’s Current Report on Form 8-K filed with the Securities and Exchange Commission (“SEC”) on October 20, 2020 and is incorporated herein by reference.
In connection with the achievement of the Approval Milestone on August 23, 2021, Cara will receive from Vifor Pharma a $50.0 million investment in Cara’s common stock at a price of $15.23 per share, equaling 3,282,391 shares of Cara’s common stock (the “Milestone Investment”). The closing of the Milestone Investment will occur within five business days following the expiration of the requisite waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976.
This Current Report on Form 8-K is not an offer to sell or the solicitation of an offer to buy shares of shares of common stock or other securities of Cara.
http://archive.fast-edgar.com/20210831/ABBO422D8C22N2Z2222H2CZZBCASZ2U2D232/tm2126615d1_8k.htm
Recent CARA News
- Cara Therapeutics Announces Exploration of Strategic Alternatives • GlobeNewswire Inc. • 07/11/2024 11:00:00 AM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 07/08/2024 08:32:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/18/2024 08:16:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/12/2024 09:12:54 PM
- Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica • GlobeNewswire Inc. • 06/12/2024 08:01:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/07/2024 08:10:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 08:05:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:28:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:26:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:25:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:24:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 08:17:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 08:10:44 PM
- Cara Therapeutics Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/13/2024 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/06/2024 08:15:59 PM
- Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024 • GlobeNewswire Inc. • 05/06/2024 11:00:00 AM
- Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/02/2024 11:00:00 AM
- Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024 • GlobeNewswire Inc. • 03/07/2024 12:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/06/2024 09:45:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 09:24:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 09:19:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 09:13:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 09:10:56 PM
- Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/04/2024 09:01:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 11:50:36 PM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM